BACK

news

Session conference—BioKorea

2019-04-03

 

Sundia will hold a session conference with Oscotec Inc. Bridge Biotherapeutics, Inc. and U-Chem at BioKorea in the morning of April 18th, 2019. We invited Dr. Jung-Ho Kim ,(Executive Director, CTO)of Oscotec Inc. and Dr. Sang Uk Kang,( SVP, Head of R&D) of Bridge Biotherapeutics, Inc. to share their views about how CRO companies can help pharmaceutical companies to better and faster get approved on IND Filing. We welcome you to participate in and discuss with us.

 

Date: WednesdayApril 18th 9:00~12:002019

Room: 301

 

 

Partnering to success on IND filing

09:00

A Start up’s Approach from Discovery to Development

  1. Jung-Ho Kim , Executive Director, CTO.   Oscotec Inc.

09:45

Drug Development Strategy in NRDO Biotech Company

  1. Sang Uk Kang, Ph.D., SVP, Head of R&D.  Bridge Biotherapeutics, Inc.

10:30

Coffee break

10:45

Points ofConsideration to US FDA IND in CMC

Dr. Hui-Yi Shiao, Director, Regulatory Affair. Sundia MediTech Company, Ltd.

11:15

Panel Discussion

  1. Jung-Ho Kim, Dr. Sang Uk Kang,  Dr. Hui-Yi Shiao,  David Kwon

11:45

Q&A

 

Also we will exhibit from Apr 17th to 19th. Our booth number is #K22.

Venue: COEX, Seoul,Korea

 

 

To make an appointment, please contact us via email info@sundia.com.

Find more information at http://www.biokorea.org/program/conference_02.asp

share this